Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study - Report - MDSpire
Advertisement
Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study
Clinical Report: Efficacy and Safety of Dupilumab in Young Children with Asthma
Overview
This retrospective cohort analysis evaluates the efficacy and safety of dupilumab in children aged 6 years and younger with uncontrolled persistent asthma. The findings indicate that dupilumab, when added to standard treatment, significantly reduces acute exacerbations, oral corticosteroid use, and emergency room visits.
Background
Asthma is a prevalent chronic respiratory condition in children, affecting approximately one in twelve in the U.S. Current treatment guidelines for young children under 6 years are limited, with few options available for those with uncontrolled asthma. Dupilumab represents a potential therapeutic option for this vulnerable population, despite being excluded from prior clinical trials.
Data Highlights
Outcome
RR at 6 months
RR at 12 months
Acute Exacerbations
0.53
0.46
OCS Use
0.67
0.66
Anaphylaxis
1.80
1.74
Key Findings
Dupilumab therapy is associated with a significant reduction in acute exacerbations at both 6 and 12 months.
Oral corticosteroid use decreased significantly in the dupilumab group compared to standard treatment alone.
Emergency room visits were reduced in children receiving dupilumab.
The risk of anaphylaxis was higher in the dupilumab cohort at both time points.
Other outcomes such as status asthmaticus and inpatient admissions showed no significant differences between groups.
Clinical Implications
The findings suggest that dupilumab may provide clinical benefits for young children with uncontrolled asthma, potentially aiding in the management of this challenging condition. However, clinicians should be aware of the increased risk of anaphylaxis associated with its use.
Conclusion
Dupilumab appears to be an effective add-on therapy for young children with persistent asthma, significantly reducing exacerbations and corticosteroid use. Further studies are warranted to confirm these findings and assess long-term safety.
